Vanguard Global Advisers
GILD icon

Vanguard Global Advisers’s Gilead Sciences GILD Stock Holding History

Vanguard Global Advisers’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342M Sell
2,704,155
-64,149
-2% -$8.45M 0.16% 95
2026
Q1 		$386M Buy
+2,768,304
New +$388M 0.21% 79

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Global Advisers's GILD Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Gilead Sciences (GILD) stake by 2.3% in Q2 2026, selling an estimated $8.45M and leaving 2,704,155 shares worth $342M. The position accounts for 0.16% of the portfolio, ranked #95.

Vanguard Global Advisers first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. The position peaked at $386M in Q1 2026. 2,169 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Vanguard Global Advisers held 2,704,155 shares of Gilead Sciences worth $342M as of Q2 2026.
  • Vanguard Global Advisers sold 64,149 Gilead Sciences shares in Q2 2026, an estimated $8.45M.
  • Gilead Sciences made up 0.16% of Vanguard Global Advisers's portfolio in Q2 2026, its #95 holding.
  • Vanguard Global Advisers first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Gilead Sciences position peaked at $386M in Q1 2026.
  • 2,169 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.